InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Cyclerion Therapeutics, Inc.

CYCN Clue Score43
United States Fiscal year ends December CIK 0001755237
Alert on the numbers Alert on insider trades

Key numbers

Fiscal year 2025, ended 31 Dec 2025, as filed
Revenue
$2.07M
Net income
$3.53M
Free cash flow
$3.31M
Operating margin
-239.8%
Net margin
-170.1%
Return on equity
-38.8%
Return on capital
-43.2%
Revenue growth, 1 yr
3.7%
Revenue growth, 5 yr
-2.0% a year

Revenue and profit

Fiscal years, as filed with the SEC · point at a year for the detail
Full statements →
2M -78M FY20 Fiscal year 2020 Revenue $2.30M Net income $77.80M Margin -3,388.6% 4M -52M FY21 Fiscal year 2021 Revenue $3.94M Net income $51.65M Margin -1,310.2% · growth +71.7% 297K -44M FY22 Fiscal year 2022 Revenue $297.00K Net income $44.08M Margin -14,841.1% · growth -92.5% 0K -5M FY23 Fiscal year 2023 Revenue $0.00 Net income $5.26M Margin n/a · growth -100.0% 2M -3M FY24 Fiscal year 2024 Revenue $2.00M Net income $3.06M Margin -152.9% 2M -4M FY25 Fiscal year 2025 Revenue $2.07M Net income $3.53M Margin -170.1% · growth +3.7%
RevenueNet incomeLoss

Latest insider transactions

From Form 4, most recent first
All of them →
DateInsiderTypeValueOf own stake
21 Nov 2024 Slate Path Capital LP
10% owner
 Sold at will $555.11K 100%
9 Aug 2023 MCGUIRE TERRANCE
Director
 Sold at will $27.16 100%
3 Jun 2021 Slate Path Capital LP
10% owner
 Bought $3.00M 15.5%
3 Jun 2021 Hecht Peter M
Chief Executive Officer
 Bought $2.70M 67.2%
3 Jun 2021 MCGUIRE TERRANCE
Director
 Bought $289.63K 15.4%
3 Jun 2021 MCGUIRE TERRANCE
Director
 Bought $10.36K 15.4%